Cogent Biosciences (COGT)


Market Price (11/16/2026): $28.54 | Market Cap: $5.0 BilSector: Health Care | Industry: Biotechnology

Cogent Biosciences (COGT)


Market Price (11/16/2026): $28.54
Market Cap: $5.0 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%

Low stock price volatility
Vol 12M is 46%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -423 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

Key risks
COGT key risks include [1] its ongoing financial losses and reliance on future funding to continue operations, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%
1 Low stock price volatility
Vol 12M is 46%
2 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
3 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10%
4 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -423 Mil
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
7 Key risks
COGT key risks include [1] its ongoing financial losses and reliance on future funding to continue operations, Show more.

COGT in ETFs

Weight = COGT's share of each fund

VTI0.01%
ITOT0.01%
IWM0.16%
VB0.07%
XBI1.2%
IWO0.36%
IBB0.34%
VTWO0.18%
+8 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 11: down 7.1% in one day (S&P 500 up 1.3%)
The stock fell today without company news, while the broader market saw gains.

Down 34.4% from its Aug 4 high to Oct 13 (S&P 500 up 1.1%)
The stock experienced a significant decline during this period, largely without explicit company news on its biggest down days. Major drops included August 11, following the company's report of second fiscal quarter 2026 financial results and business highlights, and August 28.

Nov 6: up 7.0% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock rose after the company released its third fiscal quarter 2026 financial results on November 5. The report included $0M in revenue and a net loss of $111M for the quarter.

Show more
Prices as of 11/13/2026

Nov 11: down 7.1% in one day (S&P 500 up 1.3%)
The stock fell today without company news, while the broader market saw gains.

Down 34.4% from its Aug 4 high to Oct 13 (S&P 500 up 1.1%)
The stock experienced a significant decline during this period, largely without explicit company news on its biggest down days. Major drops included August 11, following the company's report of second fiscal quarter 2026 financial results and business highlights, and August 28.

Nov 6: up 7.0% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock rose after the company released its third fiscal quarter 2026 financial results on November 5. The report included $0M in revenue and a net loss of $111M for the quarter.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -26.6% change in COGT stock from 7/31/2026 to 11/15/2026 was primarily driven by a -6.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611152026Change
Stock Price ($)38.9328.56-26.6%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)162173-6.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
COGT-26.6% 
Market (SPY)1.2%44.6%
Sector (XLV)16.6%25.1%

Fundamental Drivers

The -20.2% change in COGT stock from 4/30/2026 to 11/15/2026 was primarily driven by a -13.4% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611152026Change
Stock Price ($)35.7928.56-20.2%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)150173-13.4%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
COGT-20.2% 
Market (SPY)5.5%40.7%
Sector (XLV)30.4%18.7%

Fundamental Drivers

The 75.2% change in COGT stock from 10/31/2025 to 11/15/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511152026Change
Stock Price ($)16.3028.5675.2%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)114173-33.9%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
COGT75.2% 
Market (SPY)11.8%25.4%
Sector (XLV)33.1%12.5%

Fundamental Drivers

The 250.0% change in COGT stock from 10/31/2023 to 11/15/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311152026Change
Stock Price ($)8.1628.56250.0%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)75173-56.8%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
COGT250.0% 
Market (SPY)87.0%25.6%
Sector (XLV)59.4%18.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
COGT Return-24%35%-49%33%355%-20%154%
Peers Return-22%-46%21%-16%79%79%38%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
COGT Win Rate42%33%33%58%67%36% 
Peers Win Rate50%42%53%50%67%55% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
COGT Max Drawdown-51%-56%-74%-38%-58%-34% 
Peers Max Drawdown-57%-65%-58%-60%-47%-36% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: RVMD, RLAY, VSTM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventCOGTS&P 500
2025 US Tariff Shock
  % Loss-50.2%-18.8%
  % Gain to Breakeven101.0%23.1%
  Time to Breakeven88 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-66.8%-9.5%
  % Gain to Breakeven201.5%10.5%
  Time to Breakeven316 days24 days
2023 SVB Regional Banking Crisis
  % Loss-27.7%-6.7%
  % Gain to Breakeven38.4%7.1%
  Time to Breakeven898 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-54.9%-24.5%
  % Gain to Breakeven121.9%32.4%
  Time to Breakeven32 days427 days
2020 COVID-19 Crash
  % Loss-58.7%-33.7%
  % Gain to Breakeven141.9%50.9%
  Time to Breakeven112 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-64.4%-19.2%
  % Gain to Breakeven180.5%23.8%
  Time to Breakeven2542 days105 days

Compare to RVMD, RLAY, VSTM

In The Past

Cogent Biosciences's stock fell -50.2% during the 2025 US Tariff Shock. Such a loss loss requires a 101.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventCOGTS&P 500
2025 US Tariff Shock
  % Loss-50.2%-18.8%
  % Gain to Breakeven101.0%23.1%
  Time to Breakeven88 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-66.8%-9.5%
  % Gain to Breakeven201.5%10.5%
  Time to Breakeven316 days24 days
2023 SVB Regional Banking Crisis
  % Loss-27.7%-6.7%
  % Gain to Breakeven38.4%7.1%
  Time to Breakeven898 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-54.9%-24.5%
  % Gain to Breakeven121.9%32.4%
  Time to Breakeven32 days427 days
2020 COVID-19 Crash
  % Loss-58.7%-33.7%
  % Gain to Breakeven141.9%50.9%
  Time to Breakeven112 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-64.4%-19.2%
  % Gain to Breakeven180.5%23.8%
  Time to Breakeven2542 days105 days

Compare to RVMD, RLAY, VSTM

In The Past

Cogent Biosciences's stock fell -50.2% during the 2025 US Tariff Shock. Such a loss loss requires a 101.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Cogent Biosciences (COGT)

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's core mission is to create highly targeted treatments that address the specific genetic mutations driving various conditions, aiming to provide more effective and tailored therapeutic solutions for patients.

The company's lead product candidate is CGT9486, also known as bezuclastinib, a selective tyrosine kinase inhibitor. This investigational drug is designed to specifically inhibit the KIT D816V mutation, which is a key driver of systemic mastocytosis, a rare blood disorder. Additionally, CGT9486 targets other mutations in KIT exon 17, which are commonly found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer.

Cogent Biosciences primarily serves patients suffering from these serious and often rare diseases, including systemic mastocytosis and advanced GIST. By focusing on the underlying genetic causes, the company aims to address significant unmet medical needs within these patient populations, offering the potential for more precise and impactful therapeutic options.

AI Analysis | Feedback

1. Vertex Pharmaceuticals, but focused on specific genetic mutations like those found in systemic mastocytosis and certain gastrointestinal stromal tumors.

2. A precision-focused Novartis, developing highly targeted drugs for specific genetic mutations in diseases like systemic mastocytosis.

AI Analysis | Feedback

```html
  • CGT9486 (bezuclastinib): A selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by inhibiting specific KIT mutations.
```

AI Analysis | Feedback

Company Name (Symbol): Cogent Biosciences (COGT)

Cogent Biosciences (COGT) is a clinical-stage biotechnology company. At its current stage of operations, the company is primarily focused on the research, development, and clinical trials of its lead product candidate, CGT9486, and other pipeline therapies. As such, it does not currently have commercialized products available for sale and therefore does not have "major customers" in the traditional sense of companies or individuals purchasing its products.

Given its business model, if its product candidates successfully complete clinical development and receive regulatory approval, Cogent Biosciences would primarily sell to other companies within the healthcare ecosystem. These potential future customer categories would include:

  • Healthcare Providers: Hospitals, clinics, and other medical institutions that would administer or prescribe the company's approved therapies to patients.
  • Pharmaceutical Distributors & Pharmacies: Wholesalers, specialty pharmacies, and retail pharmacies responsible for the distribution and dispensing of prescription medications.
  • Licensing or Commercialization Partners: Other pharmaceutical or biotechnology companies with whom Cogent Biosciences might partner for co-development, licensing, or commercialization of its products in specific markets or therapeutic areas.

AI Analysis | Feedback

null

AI Analysis | Feedback

Andrew Robbins, Chief Executive Officer and President

Mr. Robbins was appointed CEO of Cogent Biosciences in October 2020. He brings over 20 years of extensive commercial, development, and strategic leadership experience within the pharmaceutical industry, with a particular focus on oncology and hematology products. Before joining Cogent, he served as Chief Operating Officer at Array Biopharma until its acquisition by Pfizer in 2019. At Array, he was instrumental in leading the sales, marketing, manufacturing, and corporate strategy teams, which culminated in the successful commercialization of Mektovi and Braftovi for BRAF mutant metastatic melanoma. Earlier in his career, Mr. Robbins held management positions at Hospira, Inc. and Pfizer Inc. as part of its Oncology business unit. He currently serves on the Board of Directors for Turmeric Acquisition Corporation.

John Green, Chief Financial Officer

Mr. Green has served as the Chief Financial Officer and Principal Accounting Officer of Cogent Biosciences since July 2020. Prior to this role, he was the Vice President of Finance and Controller at the company (then Unum Therapeutics Inc.) from April 2018 to June 2020. He possesses nearly 20 years of strategic finance and accounting experience, with approximately half of that time spent in the biotechnology industry across both public and private companies. His previous roles include Principal Accounting Officer at Merrimack Pharmaceuticals from March 2017 to June 2018, where he led the finance team through a $1.025 billion asset sale of a commercial pancreatic cancer drug and subsequent de-commercialization. He also served as Controller at Fractyl Laboratories Inc. from November 2015 to March 2017 and Director of Accounting at Dicerna Pharmaceuticals, Inc. from June 2014 to November 2015.

Cole Pinnow, Chief Commercial Officer

Mr. Pinnow was appointed Chief Commercial Officer in May 2024. He is a recognized leader in the biopharmaceutical industry with a strong background in commercial strategy and multiple successful product launches. At Cogent, he is responsible for building and leading the commercial team, including sales, marketing, access, and commercial operations, with a key focus on preparing for the potential commercial launch of bezuclastinib. He joined Cogent from Pfizer, where his roles included President and Managing Director of Pfizer Canada and Global Franchise Lead, Genitourinary and Breast Cancer Business, overseeing a $5 billion innovative cancer portfolio.

Jessica Sachs, MD, Chief Medical Officer

Dr. Sachs serves as the Chief Medical Officer at Cogent Biosciences. She is a key member of the leadership team responsible for guiding the strategic vision and operational execution of the company's clinical development programs.

John Robinson, PhD, Chief Scientific Officer

Dr. Robinson is the Chief Scientific Officer at Cogent Biosciences. He leads the Cogent Research Team, which focuses on discovering and developing novel small molecule therapies for rare, genetically driven diseases.

AI Analysis | Feedback

Cogent Biosciences (NASDAQ: COGT) faces several key risks as it progresses its lead product candidate, bezuclastinib, through clinical development and towards commercialization.

1. Dependence on Regulatory Approval and Commercialization of Bezuclastinib

Cogent Biosciences' future success and financial performance are heavily reliant on the successful regulatory approval and subsequent commercialization of its lead product candidate, bezuclastinib. The company's entire investment thesis hinges on bezuclastinib's ability to justify years of significant investment. While bezuclastinib has shown positive results in pivotal trials for systemic mastocytosis and gastrointestinal stromal tumors (GIST), and New Drug Applications (NDAs) are being submitted or are on track for submission, regulatory approval is never guaranteed. Any setbacks in regulatory approval or delays in commercialization could significantly impact the company.

2. Need for Additional Financing and Risk of Shareholder Dilution

The development and commercialization of bezuclastinib, along with other potential product candidates, require substantial capital investment. Cogent Biosciences currently operates without revenue and has reported significant net losses, including $328.94 million in 2025. The company's ability to secure additional financing, manage its expenses, and eventually generate revenue is critical for its sustained operations. There is an ongoing risk of further shareholder dilution, evidenced by past dilution and the filing of a shelf registration to provide financial flexibility.

3. Intense Competition

Cogent Biosciences operates within a highly competitive biotechnology and pharmaceutical landscape. The company faces competition from both established pharmaceutical companies with greater resources and emerging biotechs, which could challenge its ability to secure a strong market position for bezuclastinib. In systemic mastocytosis, approved therapies include avapritinib from Blueprint Medicines and midostaurin and imatinib from Novartis AG. For GIST, Cogent will compete with existing later-line tyrosine kinase inhibitors such as Bayer's Stivarga, Deciphera's Qinlock, and Blueprint's Ayvakit. Competitors with more rapid regulatory approvals or substantial resources could pose significant threats to Cogent's commercial opportunities.

AI Analysis | Feedback

null

AI Analysis | Feedback

Cogent Biosciences (COGT) focuses on developing precision therapies for genetically defined diseases, with its lead product candidate, CGT9486 (bezuclastinib), targeting systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). The addressable markets for these main products are substantial, with variations depending on the specific region and forecast period.

Systemic Mastocytosis (SM)

  • The global systemic mastocytosis treatment market is projected to grow from approximately 1.2 billion USD in 2024 to 1.9 billion USD by 2030.
  • For the United States, the systemic mastocytosis market is expected to increase from an estimated 0.36 billion USD in 2024 to 0.54 billion USD by 2030.
  • Another report indicates that the global systemic mastocytosis treatment market size is anticipated to reach 1.22 billion USD by 2033.
  • Cogent Biosciences estimates the market opportunity for Advanced Systemic Mastocytosis (AdvSM) to be approximately 500 million USD, while the market for Non-Advanced Systemic Mastocytosis (NonAdvSM) could be around 3 billion USD.

Gastrointestinal Stromal Tumors (GIST)

  • The global gastrointestinal stromal tumor market size was valued at 1.28 billion USD in 2024 and is projected to reach 2.15 billion USD by 2032.
  • Another estimate places the global gastrointestinal stromal tumor treatment market at 1.5 billion USD in 2024, with a forecast to grow to 3.2 billion USD by 2034.
  • In the 7 Major Markets (7MM), which include the United States, EU4 countries (Germany, Italy, France, and Spain), the United Kingdom, and Japan, the GIST market size was approximately 450 million USD in 2023. The United States alone accounted for about 69% of this 7MM market size in 2023, with the U.S. market reaching 561.8 million USD in 2024.
  • Cogent Biosciences estimates the GIST market to be over 4 billion USD.

AI Analysis | Feedback

Cogent Biosciences (COGT) is expected to drive future revenue growth over the next 2-3 years through the anticipated commercialization and market penetration of its lead product candidate, bezuclastinib (CGT9486), across multiple indications. The key drivers include:

  1. Launch and Uptake of Bezuclastinib in Non-Advanced Systemic Mastocytosis (Non-AdvSM): Cogent Biosciences submitted a New Drug Application (NDA) for bezuclastinib in non-advanced systemic mastocytosis in December 2025, with anticipated FDA acceptance in February 2026 and a potential commercial launch in the second half of 2026. The company has reported positive pivotal data from the SUMMIT trial, demonstrating significant improvements in symptoms and biomarkers. The U.S. moderate-to-severe non-advanced systemic mastocytosis population is estimated to be around 6,000–8,000 patients, with a total addressable market in Western countries projected to be approximately $3.5–$4 billion.
  2. Launch and Uptake of Bezuclastinib in Second-Line Gastrointestinal Stromal Tumors (GIST): The company plans to submit an NDA for bezuclastinib in GIST in April 2026, with potential commercialization by early 2027. Positive Phase 3 results from the PEAK study in imatinib-resistant or intolerant GIST patients, where bezuclastinib in combination with sunitinib significantly improved progression-free survival and objective response rates, position it to potentially become the new standard of care and the first new therapy for second-line GIST in over 20 years. Analysts have indicated a multibillion-dollar market opportunity and blockbuster revenue projections for this indication.
  3. Launch and Uptake of Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM): Cogent Biosciences is on track to submit an NDA for bezuclastinib in advanced systemic mastocytosis in the first half of 2026, with potential commercialization following FDA review, targeting full commercialization by early 2027. The APEX trial in AdvSM has also shown promising objective response rates.
  4. Market Share Capture Driven by Bezuclastinib's Differentiated Profile: Bezuclastinib's strong KIT selectivity and lack of central nervous system (CNS) penetration are highlighted as key differentiating factors, which could lead to superior symptom and biomarker responses and a better safety profile compared to existing treatments. This differentiated profile is expected to enable bezuclastinib to capture a substantial market share across its approved indications, driving significant revenue growth as it becomes a competitive option for physicians and patients.

AI Analysis | Feedback

Share Issuance

  • In November 2025, Cogent Biosciences generated approximately $475.3 million in net proceeds from concurrent public offerings of common stock and 1.625% convertible senior notes due 2031.
  • An upsized underwritten public offering in July 2025 of 25,555,556 shares of common stock at $9.00 per share, including the underwriters' option exercise, yielded net proceeds of $215.8 million.
  • The company also raised $39 million (in Q3 2025) and $24.3 million (in Q1 2025) through targeted share sales via its at-the-market (ATM) facility.

Inbound Investments

  • In June 2025, Cogent Biosciences secured a debt financing facility of up to $400 million with SLR Capital Partners, LLC, with an initial $50 million drawn at closing.

Capital Expenditures

  • Cogent Biosciences reported capital expenditures of $1.72 million for the full year 2025.
  • Capital expenditures for the full year 2024 were $0.55 million.
  • The company's research and development (R&D) expenses, a significant area of investment for a biotechnology company, totaled $269.8 million in 2025 and $232.7 million in 2024, primarily supporting clinical trials for bezuclastinib and other programs.

Peer Outperformance in Biotechnology

COGT has outperformed 92% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that COGT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
55%
of 451 industry peers · -14.8% return
3Y
90%
of 397 industry peers · 287.0% return
5Y
92%
of 364 industry peers · 176.7% return
No Biotechnology peer with a comparable growth profile has beaten COGT by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is COGT's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 10.3%56.1%108.0% CAH 517% · MCK 409% · COR 206%
Health Care Services 20 30.9%20.9%12.5% RDNT 145% · HIMS 141% · DGX 95%
Managed Health Care 8 72.3%-2.6%2.7% OSCR 155% · HQY 54% · HUM 8%
Health Care Facilities 26 18.0%25.0%-6.7% THC 257% · NHC 227% · EHC 196%
Health Care Equipment 50 7.8%11.1%-15.2% GKOS 401% · UFPT 346% · TMDX 255%
Pharmaceuticals 60 -15.0%7.7%-39.5% LQDA 1081% · KNSA 639% · XERS 572%
Health Care Supplies 11 26.2%6.1%-39.8% LNTH 241% · HAE 112% · MMSI 27%
Life Sciences Tools & Services 109 -15.3%-17.9%-74.4% AXGN 378% · MEDP 199% · NTRA 175%
Biotechnology ← 365 -26.3%-32.0%-81.4% ELVN 1259% · TRVI 1141% · DNTH 1129%
Health Care Technology 22 -20.8%-57.2%-82.3% VEEV -4% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

COGTRVMDRLAYVSTMMedian
NameCogent B.Revoluti.Relay Th.Verastem  
Mkt Price28.54171.7518.118.1823.32
Mkt Cap4.936.94.00.84.5
Rev LTM01981010055
Op Inc LTM-423-1,685-320-194-372
FCF LTM-326-1,441-214-161-270
FCF 3Y Avg-255-923-248-134-252
CFO LTM-324-1,431-214-160-269
CFO 3Y Avg-254-911-248-134-251

Growth & Margins

COGTRVMDRLAYVSTMMedian
NameCogent B.Revoluti.Relay Th.Verastem  
Rev Chg LTM--23.9%649.7%336.8%
Rev Chg 3Y Avg---17.9%--17.9%
Rev Chg Q---113.6%113.6%
QoQ Delta Rev Chg LTM--0.0%14.6%7.3%
Op Inc Chg LTM-37.5%-62.5%2.1%-21.3%-29.4%
Op Inc Chg 3Y Avg-30.0%-66.1%4.0%-36.1%-33.1%
Op Mgn LTM--853.0%-3,094.6%-193.7%-853.0%
Op Mgn 3Y Avg---3,652.1%-845.5%-2,248.8%
QoQ Delta Op Mgn LTM---95.2%-11.2%-53.2%
CFO/Rev LTM--724.5%-2,067.8%-159.1%-724.5%
CFO/Rev 3Y Avg---2,614.6%-748.0%-1,681.3%
FCF/Rev LTM--729.3%-2,067.8%-160.4%-729.3%
FCF/Rev 3Y Avg---2,623.4%-748.6%-1,686.0%

Valuation

COGTRVMDRLAYVSTMMedian
NameCogent B.Revoluti.Relay Th.Verastem  
Mkt Cap4.936.94.00.84.5
P/S-186.9383.48.3186.9
P/Op Inc-11.7-21.9-12.4-4.3-12.0
P/EBIT-12.3-20.6-12.4-4.7-12.3
P/E-12.1-19.7-13.5-4.6-12.8
P/CFO-15.2-25.8-18.5-5.2-16.9
Total Yield-8.2%-5.1%-7.4%-21.6%-7.8%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-11.5%-6.4%-20.5%-43.7%-16.0%
D/E0.00.00.00.20.0
Net D/E-0.1-0.1-0.2-0.1-0.1

Returns

COGTRVMDRLAYVSTMMedian
NameCogent B.Revoluti.Relay Th.Verastem  
1M Rtn-3.3%-3.5%11.2%-5.4%-3.4%
3M Rtn-24.8%-15.7%-8.8%24.3%-12.3%
6M Rtn-12.7%17.9%48.4%89.4%33.2%
12M Rtn-14.9%153.5%187.8%8.3%80.9%
3Y Rtn286.7%708.2%124.6%35.2%205.7%
1M Excs Rtn-1.7%-7.6%6.3%-9.8%-4.7%
3M Excs Rtn-23.0%-17.4%-10.8%15.6%-14.1%
6M Excs Rtn-15.5%15.1%45.6%86.5%30.3%
12M Excs Rtn-30.3%149.7%182.2%-15.1%67.3%
3Y Excs Rtn214.2%637.3%57.0%-58.1%135.6%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil2020201920182017
Development and commercialization of precision therapies for genetically defined diseases822108
Total822108


Operating Income by Segment
$ Mil2021
Development and commercialization of precision therapies for genetically defined diseases-76
Total-76


Net Income by Segment
$ Mil202520242023
Development and commercialization of precision therapies for genetically defined diseases-329-256-192
Total-329-256-192


Assets by Segment
$ Mil20242023202220212020
Development and commercialization of precision therapies for genetically defined diseases328313301232251
Total328313301232251


Price Behavior

Price Behavior
Market Price$28.56 
Market Cap ($ Bil)4.9 
First Trading Date03/29/2018 
Distance from 52W High-33.3% 
   50 Days200 Days
DMA Price$31.39$35.30
DMA Trenddowndown
Distance from DMA-9.0%-19.1%
 3M1YR
Volatility46.9%46.0%
Downside Capture254.83173.78
Upside Capture145.81131.78
Correlation (S&P 500)42.8%41.9%
COGT Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.991.151.761.332.521.74
Up Beta-4.79-0.631.951.815.321.97
Down Beta-1.20-0.29-0.300.600.361.30
Up Capture209%153%174%119%454%832%
Bmk +ve Days12182862130427
Stock +ve Days9172559111368
Down Capture213%208%264%157%141%110%
Bmk -ve Days10253664121325
Stock -ve Days13253866138373

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with COGT
COGT-19.1%46.0%-0.33-
Sector ETF (XLV)25.8%16.8%1.1823.5%
Equity (SPY)11.6%13.7%0.5441.5%
Gold (GLD)-7.9%28.9%-0.2920.7%
Commodities (DBC)33.8%21.3%1.26-19.2%
Real Estate (VNQ)10.7%14.2%0.4716.3%
Bitcoin (BTCUSD)-33.0%43.7%-0.7920.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with COGT
COGT21.0%93.9%0.56-
Sector ETF (XLV)9.1%15.4%0.3917.7%
Equity (SPY)11.5%17.3%0.4922.9%
Gold (GLD)15.9%19.2%0.669.4%
Commodities (DBC)7.8%19.6%0.280.6%
Real Estate (VNQ)1.3%18.9%-0.0417.5%
Bitcoin (BTCUSD)2.2%51.6%0.2314.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with COGT
COGT-6.5%162.2%0.33-
Sector ETF (XLV)13.0%16.8%0.6410.7%
Equity (SPY)15.5%18.0%0.7313.3%
Gold (GLD)11.1%16.6%0.546.2%
Commodities (DBC)7.6%18.1%0.333.9%
Real Estate (VNQ)6.3%20.7%0.267.9%
Bitcoin (BTCUSD)58.4%66.2%0.987.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity17.4 Mil
Short Interest: % Change Since 10152026-11.4%
Average Daily Volume2.0 Mil
Days-to-Cover Short Interest8.7 days
Basic Shares Quantity173.1 Mil
Short % of Basic Shares10.1%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/20267.0%-1.5% 
8/10/2026-2.0%-10.5%-16.8%
5/5/20260.7%-7.2%-12.2%
2/17/20263.0%1.5%-3.0%
11/3/2025-4.9%-9.1%140.2%
8/5/2025-5.7%-9.3%8.5%
5/6/2025-15.6%-7.9%1.3%
2/25/2025-6.3%-6.2%-7.5%
...
SUMMARY STATS   
# Positive171012
# Negative81512
Median Positive2.7%11.2%16.1%
Median Negative-5.3%-7.9%-9.2%
Max Positive7.6%28.2%140.2%
Max Negative-15.6%-28.1%-22.3%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/20267.0%-1.5% 
8/10/2026-2.0%-10.5%-16.8%
5/5/20260.7%-7.2%-12.2%
2/17/20263.0%1.5%-3.0%
11/3/2025-4.9%-9.1%140.2%
8/5/2025-5.7%-9.3%8.5%
5/6/2025-15.6%-7.9%1.3%
2/25/2025-6.3%-6.2%-7.5%
11/12/2024-0.2%-13.6%-10.9%
8/6/20241.3%-7.0%25.6%
5/7/20242.5%-2.9%17.8%
2/26/20240.8%-2.8%-22.3%
11/2/20234.5%-10.2%-2.7%
8/8/20237.6%9.9%14.3%
5/9/20232.4%0.5%-1.2%
3/14/20237.5%-6.2%-18.4%
11/14/2022-2.3%-8.5%-3.8%
8/9/20223.1%16.0%34.6%
5/10/2022-8.3%-28.1%-17.3%
3/15/20224.3%28.2%66.5%
11/10/20212.7%16.8%-7.5%
8/16/20211.6%13.4%1.6%
5/12/20211.5%6.8%2.2%
3/16/20216.7%12.5%6.0%
11/9/20202.6%9.8%27.6%
SUMMARY STATS   
# Positive171012
# Negative81512
Median Positive2.7%11.2%16.1%
Median Negative-5.3%-7.9%-9.2%
Max Positive7.6%28.2%140.2%
Max Negative-15.6%-28.1%-22.3%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/10/202610-Q
03/31/202605/05/202610-Q
12/31/202502/17/202610-K
09/30/202511/07/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/25/202510-K
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202302/26/202410-K
09/30/202311/07/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/14/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/10/202610-Q
03/31/202605/05/202610-Q
12/31/202502/17/202610-K
09/30/202511/07/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/25/202510-K
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202302/26/202410-K
09/30/202311/07/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/14/202310-K
09/30/202211/14/202210-Q
06/30/202208/09/202210-Q
03/31/202205/10/202210-Q
12/31/202103/15/202210-K
09/30/202111/10/202110-Q
06/30/202108/16/202110-Q
03/31/202105/12/202110-Q
12/31/202003/16/202110-K
09/30/202011/09/202010-Q
06/30/202008/11/202010-Q
03/31/202005/11/202010-Q
12/31/201903/26/202010-K

Insider Activity

Updated 10/5/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Morris, Arlene DirectSell831202637.1245,510  Form
2Fairmount, Funds Management LlcFairmount Healthcare Fund II LPSell331202634.667,000,000242,620,000190,748,468Form
3Fairmount, Funds Management LlcFairmount Healthcare Fund II LPSell122202636.403,500,000127,400,000200,324,415Form
4Kearns, EvanChief Legal OfficerDirectSell1230202538.7065,0002,515,5004,233,703Form
5Green, John LChief Financial OfficerDirectSell1230202538.6877,0002,978,3605,099,339Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Morris, Arlene DirectSell831202637.1245,510  Form
2Fairmount, Funds Management LlcFairmount Healthcare Fund II LPSell331202634.667,000,000242,620,000190,748,468Form
3Fairmount, Funds Management LlcFairmount Healthcare Fund II LPSell122202636.403,500,000127,400,000200,324,415Form
4Kearns, EvanChief Legal OfficerDirectSell1230202538.7065,0002,515,5004,233,703Form
5Green, John LChief Financial OfficerDirectSell1230202538.6877,0002,978,3605,099,339Form
6Sachs, JessicaChief Medical OfficerDirectSell1230202538.7082,6423,198,2455,183,401Form
7Robinson, John EdwardChief Scientific OfficerDirectSell1230202538.7490,0003,486,6005,423,677Form

Investor Activity (13F)

Updated Nov 16, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Fairmount Funds Management LLC$211.8 Mil15.3%12TRIM -38.9%13F
Elmind Capital, LP$45.1 Mil12.8%34Hold13F
Octagon Capital Advisors LP$90.5 Mil10.0%29Hold13F
Kynam Capital Management, LP$155.4 Mil9.9%36TRIM -34.5%13F
Commodore Capital LP$111.2 Mil6.4%36ADD +31.5%13F
TCG Crossover Management, LLC$190.4 Mil5.4%49TRIM -15.7%13F
Saturn V Capital Management LP$24.1 Mil4.4%21TRIM -48.5%13F
First Turn Management, LLC$36.5 Mil4.1%33ADD +14.9%13F
Patient Square Capital LP$22.9 Mil4.1%29ADD +87.8%13F
Venrock Adviser, LLC$77.0 Mil2.9%33Hold13F
Defilade Capital Management, L.P.$13.6 Mil1.9%31TRIM -38.0%13F
Redmile Group, LLC$26.5 Mil1.8%35TRIM -52.2%13F
Vivo Capital, LLC$16.3 Mil1.4%46TRIM -82.4%13F
Cormorant Asset Management, LP$7.7 Mil0.4%46TRIM -11.1%13F
Evergreen Quality Fund GP, Ltd.$9.6 Mil0.2%40Hold13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Patient Square Capital LP$22.9 Mil4.1%29ADD +87.8%13F
Commodore Capital LP$111.2 Mil6.4%36ADD +31.5%13F
First Turn Management, LLC$36.5 Mil4.1%33ADD +14.9%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Vivo Capital, LLC$16.3 Mil1.4%46TRIM -82.4%13F
Redmile Group, LLC$26.5 Mil1.8%35TRIM -52.2%13F
Saturn V Capital Management LP$24.1 Mil4.4%21TRIM -48.5%13F
Fairmount Funds Management LLC$211.8 Mil15.3%12TRIM -38.9%13F
Defilade Capital Management, L.P.$13.6 Mil1.9%31TRIM -38.0%13F
Kynam Capital Management, LP$155.4 Mil9.9%36TRIM -34.5%13F
TCG Crossover Management, LLC$190.4 Mil5.4%49TRIM -15.7%13F
Cormorant Asset Management, LP$7.7 Mil0.4%46TRIM -11.1%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Fairmount Funds Management LLC$211.8 Mil15.3%12TRIM -38.9%13F
TCG Crossover Management, LLC$190.4 Mil5.4%49TRIM -15.7%13F
Kynam Capital Management, LP$155.4 Mil9.9%36TRIM -34.5%13F
Commodore Capital LP$111.2 Mil6.4%36ADD +31.5%13F
Octagon Capital Advisors LP$90.5 Mil10.0%29Hold13F
Venrock Adviser, LLC$77.0 Mil2.9%33Hold13F
Elmind Capital, LP$45.1 Mil12.8%34Hold13F
First Turn Management, LLC$36.5 Mil4.1%33ADD +14.9%13F
Redmile Group, LLC$26.5 Mil1.8%35TRIM -52.2%13F
Saturn V Capital Management LP$24.1 Mil4.4%21TRIM -48.5%13F
Patient Square Capital LP$22.9 Mil4.1%29ADD +87.8%13F
Vivo Capital, LLC$16.3 Mil1.4%46TRIM -82.4%13F
Defilade Capital Management, L.P.$13.6 Mil1.9%31TRIM -38.0%13F
Evergreen Quality Fund GP, Ltd.$9.6 Mil0.2%40Hold13F
Cormorant Asset Management, LP$7.7 Mil0.4%46TRIM -11.1%13F
Core Cache Last Updated: 11/15/2026